Johnson & Johnson Reaches $5.5 Billion Settlement in Talc Litigation

Source: Amanda Bronstad, “Johnson & Johnson Settles 76,000 Talcum Powder Lawsuits for $5.5B,” Law.com, July 27, 2026. This post summarizes reporting from Law.com and does not reproduce the original article.

Johnson & Johnson has agreed to a global settlement resolving approximately 76,000 lawsuits alleging that its talc-based baby powder caused ovarian cancer.

According to a July 27, 2026, report by Amanda Bronstad of Law.com, the settlement is expected to resolve approximately 99.75% of the talc cases pending in federal and state courts. Johnson & Johnson has committed at least $5.5 billion to the resolution, including $3 billion scheduled to be paid in 2027.

The agreement is uncapped and uses a tiered compensation grid based on specified claimant criteria. The settlement is contingent on participation by at least 95% of eligible claimants. Plaintiffs’ counsel has indicated that the final value could ultimately reach between $6 billion and $7 billion.

The agreement follows years of trials, appeals and three unsuccessful bankruptcy proceedings involving Johnson & Johnson subsidiaries. It also comes shortly after a federal magistrate judge ordered plaintiffs to explain why remaining multidistrict litigation claims should not be dismissed following the withdrawal of two specific-causation experts from bellwether cases.

Plaintiffs’ attorneys involved in negotiating the settlement include Christopher Seeger of Seeger Weiss, R. Bryant McCulley of Ashcraft & Gerel and Hunter Shkolnik of Napoli Shkolnik. Johnson & Johnson’s lead negotiating attorney was Jim Murdica of Barnes & Thornburg.

If the participation threshold is met, the agreement would represent a significant step toward resolving litigation that has continued for approximately 15 years.

For counsel and claimants, the next phase will likely require substantial coordination around claimant eligibility, participation decisions, documentation review, compensation classifications and the administration of settlement payments.

Talc MDL Judge Orders Thousands of Plaintiffs to Defend Their Claims

Source: Synopsis based on reporting by Amanda Bronstad for Law.com, published July 22, 2026.

A federal magistrate judge has ordered approximately 67,000 plaintiffs in the Johnson & Johnson talc multidistrict litigation to explain why their ovarian cancer claims should not be dismissed.

U.S. Magistrate Judge Rukhsanah Singh expressed “deep skepticism” about whether plaintiffs can present reliable expert testimony establishing that talc specifically caused their cancer. The order followed the withdrawal—and attempted reinstatement—of two gynecological oncology experts whose testimony raised questions about other potential risk factors and the scientific methods used to determine causation.

Judge Singh described the order as an opportunity to reassess how the court manages an MDL that has been pending for more than a decade. Plaintiffs have until November 19, 2026, to respond. U.S. District Judge Michael Shipp has also scheduled an August 3 hearing.

Johnson & Johnson characterized the ruling as a significant step toward dismissal, while plaintiffs have argued that applying findings from six bellwether cases across the broader inventory could raise due process concerns.

The development places increased pressure on plaintiffs’ leadership to evaluate expert support, claimant-specific evidence, and the overall strength of tens of thousands of pending cases.

On March 2, a three-judge appeals panel in New Jersey overturned two verdicts totaling more than $83 million against Johnson & Johnson and C.R. Bard, Inc. on the grounds that the trial court had erred by preventing the defendants from presenting certain evidence to the two juries who made the awards in 2017 and 2018.

The  appeals court consolidated two cases – those of plaintiffs Elizabeth and Tadeusz Hrymoc, and Mary and Thomas Walsh McGinnis – who alleged that they had suffered severe complications, including chronic pain from the use of the pelvic mesh medical device manufactured by Ethicon, a J&J subsidiary, and Bard, a subsidiary of global medical supplier Becton-Dickinson. The jury in the Hrymoc case found that Ethicon was liable under theories of defective design and inadequate warning, resulting in an award of $15 million in compensatory and punitive damages. The jury in the case brought by Ms. McGinnis found Bard liable for design defects and failure to warn as well, awarding $68 million in compensatory and punitive damages.

In overturning the two verdicts, the New Jersey appeals court ruled that, at trial, the presiding judges erred by categorically excluding any proof that defendants had obtained what is known as ‘’’Section 510(k) clearance’ from the U.S. Food and Drug Administration for the devices implanted by plaintiffs’ surgeons.” In response to the defendants’ arguments that they were harmed by being precluded from presenting evidence to the jury that they had received the Section 510(k) clearance from the FDA which they maintained would have proved that their products were substantially equivalent to a device already on the market in terms of design and safety, the appeals panel vacated both jury awards and remanded the cases for new trials; they also ordered new hearings on the admissibility of the 510(k) evidence. The panel rejected the defendants’ additional evidentiary and substantive arguments.

In response to the appellate ruling, counsel for McGinnis, Adam Slater, stated that it had been foreseeable that the 510(k) issue would be headed to the New Jersey Supreme Court, adding that notwithstanding the appeals panel’s findings, the decisions by the trial judges were consistent with other courts including the Fourth, Seventh and Eleventh Circuit Courts of Appeals. Mr. Slater also noted that the appeals court had affirmed the other issues in favor of the plaintiffs, including the amounts of the two awards.